# US 2005/0038006 A1 · Triphasic oral contraceptive

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0038006 A1
- Document ID: US20050038006A1
- Status: Published application
- Kind: A1
- Application number: 10/945,698
- Filed: 2004-09-21
- Published: 2005-02-17
- Earliest claimed: 1998-12-23
- Inventors: Gary Shangold; Arkady Rubin; David Upmalis
- Web page: https://patentgrep.com/patent/US20050038006A1

## CPC

- A61K 31/565: not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method of contraception in which an estrogen and desogestrel are administered daily in a three phase sequence for 21 days is disclosed. In the first phase a combination of an estrogen and a progestogen in a low but contraceptively effective daily dosage corresponding in estrogenic activity to 23-28 μg of 17α-ethinylestradiol and in progestogenic activity to 0.065-0.75 of norethindrone is administered for 5-8 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.25-1.0 mg of norethindrone for 7-11 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.35-2.0 mg of norethindrone for 3-7 days; followed by 4-8 days without administering either an estrogen or a progestogen, provided that the progestin dose should increase from the first phase to the second phase to the third phase, that the progestin is desogestrel at a dose in each phase of between of from 0.05-1.0 mg/day and that the dosage of estrogen is kept constant in each phase.

## Claims

### Claim at position 1

1-22. (cancelled).

### Claim 23

A method of contraception which comprises administering for 21 successive days to a female of child bearing age a combination of ethinyl estradiol and desogestrel in a contraceptively effective daily dosage in which there is a first phase of 7 days wherein the combination comprises an ethinyl estradiol daily dosage of 25 μg and a desogestrel daily dosage of 0.100 mg; followed by a second phase of 7 days wherein the combination comprises an ethinyl estradiol daily dosage of 25 μg and a desogestrel daily dosage of 0.125 mg; followed by a third phase of 7 days wherein the combination comprises an ethinyl estradiol daily dosage of 25 μg and a desogestrel daily dosage of 0.150 mg; and followed by 7 days free of estrogen and desogestrel administration.

### Claim 24

A triphasic oral contraceptive unit having 21 separate dosage units adapted for successive daily oral administration comprising: 7 dosage units containing, in admixture with a pharmaceutically acceptable carrier, a combination of an ethinyl estradiol daily dosage of 25 μg and a desogestrel daily dosage of 0.100 mg as a first phase; followed by 7 dosage units containing, in admixture with a pharmaceutically acceptable carrier, a combination of an ethinyl estradiol daily dosage of 25 μg and a desogestrel daily dosage of 0.125 mg as a second phase; followed by 7 dosage units containing, in admixture with a pharmaceutically acceptable carrier, an ethinyl estradiol daily dosage of 25 μg and a desogestrel daily dosage of 0.150 mg as a third phase; and optionally containing 7 additional dosage units free of ethinyl estradiol and desogestrel.
